Behmanesh Elham, Delavar Mouloud Agajani, Kamalinejad Mohammad, Khafri Soraya, Shirafkan Hoda, Mozaffarpur Seyyed Ali
Department of Persian Medicine, School of Persian Medicine, Babol University of Medical Sciences, Babol, Iran.
Infertility and Reproductive Health Research Center, Babol University of Medical Sciences, Babol, Iran.
Taiwan J Obstet Gynecol. 2019 Mar;58(2):227-233. doi: 10.1016/j.tjog.2019.01.011.
This study strove to investigate the safety and effectiveness of Eryngo in the treatment of primary dysmenorrhea.
The researchers conducted a blinded, randomized, trial design on 169 women, 15-30 years of age, who had been diagnosed with primary dysmenorrhea at Babol University of Medical Sciences. Subjects were randomly assigned to receive 5 ml syrup of Eryngo, placebo, or Ibuprofen (200 mg) three times a day (15 ml/day), from one day prior to the onset of bleeding for five days. The degree of dysmenorrhea was reported by two measures; Visual analogue scale (VAS), as a primary outcome, and the assessment of dysmenorrhea severity (VMS), as a secondary outcome at 4 menstrual cycles: at pretreatment phase, at the first menstrual cycle, at the second menstrual cycle, and the third menstrual cycle without drug.
The reduced peak-pain differed by the treatment length in women treated for two menstrual cycles: 4.2 (1.0) cm in the Eryngo group, 4.3 (0.0) cm in the Ibuprofen group, and 0.9 (0.1) cm in the placebo group (P < 0.0001). No serious side effects were reported in all groups under study. According to the results, minor side effects did not increase in the Eryngo group when compared with the placebo group.
Eryngo relieved dysmenorrhea as effectively as Ibuprofen did. Thus, Eryngo could be regarded as a new herbal remedy for the treatment of dysmenorrhea. However, in order to prescribe Eryngo as herbal remedy, rigorous research studies are required to establish its efficacy by investigating its chemical, pharmacologic, and therapeutic properties.
本研究旨在探讨刺蒺藜治疗原发性痛经的安全性和有效性。
研究人员对169名年龄在15至30岁之间、在巴博尔医科大学被诊断为原发性痛经的女性进行了一项双盲、随机试验设计。受试者被随机分配，从出血开始前一天起连续五天，每天三次（15毫升/天）服用5毫升刺蒺藜糖浆、安慰剂或布洛芬（200毫克）。痛经程度通过两种测量方法报告：视觉模拟量表（VAS）作为主要结果，痛经严重程度评估（VMS）作为次要结果，在4个月经周期进行评估：治疗前阶段、第一个月经周期、第二个月经周期以及第三个无药物治疗的月经周期。
在接受两个月经周期治疗的女性中，疼痛峰值降低程度因治疗时间而异：刺蒺藜组为4.2（1.0）厘米，布洛芬组为4.3（0.0）厘米，安慰剂组为0.9（0.1）厘米（P < 0.0001）。在所有研究组中均未报告严重副作用。根据结果，与安慰剂组相比，刺蒺藜组的轻微副作用并未增加。
刺蒺藜缓解痛经的效果与布洛芬相当。因此，刺蒺藜可被视为一种治疗痛经的新型草药疗法。然而，为了将刺蒺藜作为草药疗法开出处方，需要通过研究其化学、药理和治疗特性来进行严格的研究以确定其疗效。
